RT Journal Article
SR Electronic
T1 SARS-CoV-2: Proof of recombination between strains and emergence of possibly more virulent ones
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.11.20229765
DO 10.1101/2020.11.11.20229765
A1 Haddad, Dania
A1 John, Sumi Elsa
A1 Mohammad, Anwar
A1 Hammad, Maha M
A1 Hebbar, Prashantha
A1 Channanath, Arshad
A1 Nizam, Rasheeba
A1 Al-Qabandi, Sarah
A1 Madhoun, Ashraf Al
A1 Alshukry, Abdullah
A1 Ali, Hamad
A1 Thanaraj, Thangavel Alphonse
A1 Al-Mulla, Fahd
YR 2020
UL http://medrxiv.org/content/early/2020/11/15/2020.11.11.20229765.abstract
AB COVID-19 is challenging healthcare preparedness, world economies, and livelihoods. The infection and death rates associated with this pandemic are strikingly variable in different countries. To elucidate this discrepancy, we analyzed 2431 early spread SARS-CoV-2 sequences from GISAID. We estimated continental-wise admixture proportions, assessed haplotype block estimation, and tested for the presence or absence of strains recombination. Herein, we identified 1010 unique missense mutations and seven different SARS-CoV-2 clusters. In samples from Asia, a small haplotype block was identified; whereas, samples from Europe and North America harbored large and different haplotype blocks with nonsynonymous variants. Variant frequency and linkage disequilibrium varied among continents, especially in North America. Recombination between different strains was only observed in North American and European sequences. Additionally, we structurally modeled the two most common mutations D614G and P314L which suggested that these linked mutations may enhance viral entry and stability. Overall, we propose that COVID-19 virulence may be more severe in Europe and North America due to coinfection with different SARS-CoV-2 strains leading to genomic recombination which might be challenging for current treatment regimens and vaccine development. Furthermore, our study provides a possible explanation for the more severe second wave of COVID-19 that many countries are currently experiencing presented as higher rates of infection and death.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Coronavirus emergency resilience grant from Kuwait Foundation for the Advancement of Sciences.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We gratefully acknowledge the authors from originating and submitting laboratories of the sequences in GISAID EpiFlu Database on which this research is based. All data submitters may be contacted directly via www.gisaid.org.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated for this study are available on request to the corresponding author.